Use of Residential Blood Pressure Monitoring as a Tool in Pharmaceutical Care - Baseline Assessment of the MINOR Clinical Trial

Abstract

Objective: To identify the contributions of home blood pressure monitoring (HBPM) devices for the assessment and monitoring of antihypertensive therapy in patients attended at a public clinical pharmacy service.

Methods: A longitudinal study with secondary analysis was conducted, using IBM SPSS Statistics software, of the data aggregated to the baseline database of the MINOR Clinical Trial, registered on ClinicalTrials.gov under number NCT04861727 and approved by the Research Ethics Committee of the Federal University of Bahia, Opinion No. 4.595.144.

Main findings: In the baseline HBPM assessment, the presence of hypotension was confirmed in 22.98% of the participants (n=74), controlled hypertension in only 15.84% (n=51) of the followed patients, and 61.18% of the individuals (n=166) were confirmed with uncontrolled hypertension. After the pharmaceutical interventions, the rate of patients with hypotension decreased to 20.81% (n=67), controlled hypertension increased to 36.34% (n=117), and the rate of patients with uncontrolled hypertension decreased to 42.86% (n=138).

Conclusions: There were positive contributions in the use of HBPM and benefits regarding its use as a tool for optimizing antihypertensive pharmacotherapy within the scope of clinical pharmaceutical care, adequate control in the management of hypertension, and pharmaceutical care in Primary Health Care.